Dr. William D. Doty, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1975)
- Years since graduation
- 51
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 553
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1975Medical school: University of Alabama School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
FL license ME36607 · AL license 7355
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sacred Heart Hospital Pensacola, FL
- Baptist Hospital Pensacola, FL
- Gulf Breeze Hospital Gulf Breeze, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 553
- Services billed
- 3,087
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 722 | 124 |
| Established patient office or other outpatient visit, 30-39 minutes | 337 | 269 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 308 | 151 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 226 | 216 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 142 | 136 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 138 | 57 |
| Established patient office or other outpatient visit, 40-54 minutes | 127 | 108 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 96 | 84 |
| Ultrasound of both sides of head and neck blood flow | 82 | 73 |
| New patient office or other outpatient visit, 45-59 minutes | 45 | 45 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Pensacola, FL | 602 |
| Metoprolol Succinate Other prescribers in Pensacola, FL | 258 |
| Eliquis (apixaban) Other prescribers in Pensacola, FL | 187 |
| Ezetimibe Other prescribers in Pensacola, FL | 176 |
| Isosorbide Mononitrate Er (isosorbide mononitrate) Other prescribers in Pensacola, FL | 121 |
| Nitroglycerin Other prescribers in Pensacola, FL | 121 |
| Spironolactone Other prescribers in Pensacola, FL | 102 |
| Furosemide Other prescribers in Pensacola, FL | 86 |
| Amlodipine Besylate Other prescribers in Pensacola, FL | 86 |
| Carvedilol Other prescribers in Pensacola, FL | 84 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 16 payments worth $391 in total to this clinician.
| Kestra Medical Technology Services, Inc. | $127 |
|---|---|
| Merck Sharp & Dohme LLC | $80.02 |
| Novartis Pharmaceuticals Corporation | $32.43 |
| GlaxoSmithKline, LLC. | $31.14 |
| Boston Scientific Corporation | $28.85 |
| Esperion Therapeutics, Inc. | $22.17 |
| Agepha Pharma Fz LLC | $20.64 |
| Abb Con-cise Optical Group LLC | $17.17 |
| Food and Beverage | $391 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,109 in research payments for these studies, mostly to the institutions running them.
- A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.